EU legal adviser urges voiding wastewater treatment fee for drugmakers

The short version

• An EU advocate general recommended annulling a rule requiring pharmaceutical and cosmetic companies to fund at least 80% of wastewater treatment costs.[STAT]
• The directive took effect early last year to curb dangerous urban wastewater discharges and protect human health and the environment.[STAT]
• The broader program features a treatment phase targeting micropollutants and was projected to yield approximately $7.5 billion in annual savings by 2040.[STAT]
• Under the directive, European Union member states face a December 2028 deadline to secure corporate financial contributions.[STAT]

Key facts

• An EU advocate general recommended striking down part of a directive obligating pharmaceutical and cosmetic manufacturers to cover at least 80% of wastewater treatment expenses.[STAT]
• The updated wastewater directive took effect early last year with the goal of mitigating health and environmental hazards from urban wastewater.[STAT]
• The initiative targets micropollutants generated primarily by pharmaceutical and cosmetic products via a quaternary treatment phase.[STAT]
• EU member states are required to ensure relevant companies pay into waste treatment programs by December 2028.[STAT]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• STAT+: Pharma wins a battle over the cost of wastewater treatment in EuropeSTAT metered